"Chemokine CCL2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chemokine that is a chemoattractant for MONOCYTES and may also cause cellular activation of specific functions related to host defense. It is produced by LEUKOCYTES of both monocyte and lymphocyte lineage and by FIBROBLASTS during tissue injury. It has specificity for CCR2 RECEPTORS.
| Descriptor ID |
D018932
|
| MeSH Number(s) |
D12.644.276.374.200.110.990.600 D12.776.467.374.200.110.990.600 D23.125.300.110.990.600 D23.469.200.110.990.600 D23.529.374.200.110.990.500
|
| Concept/Terms |
Chemokine CCL2- Chemokine CCL2
- CCL2, Chemokine
- Monocyte Chemotactic and Activating Factor
- Monocyte Chemoattractant Protein-1
- Chemoattractant Protein-1, Monocyte
- Monocyte Chemoattractant Protein 1
- Chemokines CCL2
- CCL2, Chemokines
- CCL2 Chemokine
- Chemokine, CCL2
- Chemokine (C-C Motif) Ligand 2
- Monocyte Chemotactic Protein-1
- Chemotactic Protein-1, Monocyte
- Monocyte Chemotactic Protein 1
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CCL2".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CCL2".
This graph shows the total number of publications written about "Chemokine CCL2" by people in this website by year, and whether "Chemokine CCL2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 2 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 1 | 3 |
| 2005 | 2 | 2 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 3 | 4 |
| 2010 | 0 | 3 | 3 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 6 | 8 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 3 | 1 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 3 | 0 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemokine CCL2" by people in Profiles.
-
Messeha SS, Zarmouh NO, Antonie L, Soliman KFA. Sanguinarine Inhibition of TNF-a-Induced CCL2, IKBKE/NF-?B/ERK1/2 Signaling Pathway, and Cell Migration in Human Triple-Negative Breast Cancer Cells. Int J Mol Sci. 2022 Jul 28; 23(15).
-
Kanga KJW, Mendonca P, Soliman KFA, Ferguson DT, Darling-Reed SF. Effect of Diallyl Trisulfide on TNF-a-induced CCL2/MCP-1 Release in Genetically Different Triple-negative Breast Cancer Cells. Anticancer Res. 2021 Dec; 41(12):5919-5933.
-
Wang Y, Tiruthani K, Li S, Hu M, Zhong G, Tang Y, Roy S, Zhang L, Tan J, Liao C, Liu R. mRNA Delivery of a Bispecific Single-Domain Antibody to Polarize Tumor-Associated Macrophages and Synergize Immunotherapy against Liver Malignancies. Adv Mater. 2021 Jun; 33(23):e2007603.
-
Thomas MU, Messex JK, Dang T, Abdulkadir SA, Jorcyk CL, Liou GY. Macrophages expedite cell proliferation of prostate intraepithelial neoplasia through their downstream target ERK. FEBS J. 2021 03; 288(6):1871-1886.
-
Messeha SS, Zarmouh NO, Mendonca P, Cotton C, Soliman KFA. Molecular mechanism of gossypol mediating CCL2 and IL-8 attenuation in triple-negative breast cancer cells. Mol Med Rep. 2020 08; 22(2):1213-1226.
-
Hao Q, Vadgama JV, Wang P. CCL2/CCR2 signaling in cancer pathogenesis. Cell Commun Signal. 2020 05 29; 18(1):82.
-
Chompre G, Martinez-Orengo N, Cruz M, Porter JT, Noel RJ. TGF?RI antagonist inhibits HIV-1 Nef-induced CC chemokine family ligand 2 (CCL2) in the brain and prevents spatial learning impairment. J Neuroinflammation. 2019 Dec 11; 16(1):262.
-
Mendonca P, Horton A, Bauer D, Messeha S, Soliman KFA. The inhibitory effects of butein on cell proliferation and TNF-a-induced CCL2 release in racially different triple negative breast cancer cells. PLoS One. 2019; 14(10):e0215269.
-
Messeha SS, Zarmouh NO, Mendonca P, Alwagdani H, Kolta MG, Soliman KFA. The inhibitory effects of plumbagin on the NF-?B pathway and CCL2 release in racially different triple-negative breast cancer cells. PLoS One. 2018; 13(7):e0201116.
-
Dutta P, Sarkissyan M, Paico K, Wu Y, Vadgama JV. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis. Breast Cancer Res Treat. 2018 Aug; 170(3):477-486.